TY - JOUR
T1 - Monoinstitutional real world experience in management of vinflunine as second line therapy for transitional cell carcinoma of the urothelium
AU - Schinzari, Giovanni
AU - Rossi, Ernesto
AU - Pierconti, Francesco
AU - Garufi, Giovanna
AU - Monterisi, Santa
AU - Strippoli, Antonia
AU - D'Argento, Ettore
AU - Cassano, Alessandra
AU - Barone, Carlo Antonio
PY - 2018
Y1 - 2018
N2 - Vinflunine is the only cytotoxic agent tested as a second line therapy in transitional cell carcinoma of the urothelium in a phase III trial. It is not largely employed in clinical practice because of the high incidence of grade 3-4 toxicity. We evaluated efficacy and safety of Vinflunine at the dose of 280 mg/m2 every 3 weeks associated with primary prophylaxis with granulocyte growth factors and laxatives for patients progressed after platinum + Gemcitabine. Overall survival was 8.5 months, progression-free survival 4.33 months and response rate 25%, with disease control rate 57.2%. Grade III-IV neutropenia occurred in 10.7% of the patients, grade III-IV anemia and grade III thrombocytopenia in 10.7% and 7.2%, respectively. Among non haematological toxicity, grade I-II constipation was reported in 14.2% of the patients, without grade III-IV adverse events. No discontinuation for toxicity was observed. This study underlines that Vinfluinine at a dose of 280 mg/m2associated with primary prophylaxis for neutropenia and constipation is effective and with a favorable toxicity profile.
AB - Vinflunine is the only cytotoxic agent tested as a second line therapy in transitional cell carcinoma of the urothelium in a phase III trial. It is not largely employed in clinical practice because of the high incidence of grade 3-4 toxicity. We evaluated efficacy and safety of Vinflunine at the dose of 280 mg/m2 every 3 weeks associated with primary prophylaxis with granulocyte growth factors and laxatives for patients progressed after platinum + Gemcitabine. Overall survival was 8.5 months, progression-free survival 4.33 months and response rate 25%, with disease control rate 57.2%. Grade III-IV neutropenia occurred in 10.7% of the patients, grade III-IV anemia and grade III thrombocytopenia in 10.7% and 7.2%, respectively. Among non haematological toxicity, grade I-II constipation was reported in 14.2% of the patients, without grade III-IV adverse events. No discontinuation for toxicity was observed. This study underlines that Vinfluinine at a dose of 280 mg/m2associated with primary prophylaxis for neutropenia and constipation is effective and with a favorable toxicity profile.
KW - Oncology
KW - Second line
KW - Toxicity
KW - Transitional cell carcinoma of the urothelium
KW - Vinflunine
KW - Oncology
KW - Second line
KW - Toxicity
KW - Transitional cell carcinoma of the urothelium
KW - Vinflunine
UR - http://hdl.handle.net/10807/122904
UR - http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5b%5d=24162&path%5b%5d=75949
U2 - 10.18632/oncotarget.24162
DO - 10.18632/oncotarget.24162
M3 - Article
SN - 1949-2553
VL - 9
SP - 8765
EP - 8771
JO - Oncotarget
JF - Oncotarget
ER -